ASH 2023 | Dual-targeted regimens for the treatment of CLL: anti-CD20 antibodies, BTKi, and BCL2i
Chaitra Ujjani, MD, University of Washington & Fred Hutchinson Cancer Research Center, Seattle, WA, gives an overview of dual-targeted regimens for the treatment of chronic lymphocytic leukemia (CLL). These regimens involve combinations of anti-CD20 antibodies, BTK inhibitors (BTKi), and BCL2 inhibitors (BCL2i), which have been studied in the ECOG-E1912 (NCT02048813), FLAIR (ISRCTN01844152), and ELEVATE-TN (NCT02475681) trials. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Lilly, Janssen, Pharmacyclics, Genentech, Beigene, Kite, a Gilead Company, Epizyme, Astrazeneca, Abbvie, Atara; Honoraria: Lilly, Janssen, Pharmacyclics, Genentech, Beigene, Astrazeneca, Abbvie; Research Funding: Lilly, Pharmacyclics, PCYC, Kite, a Gilead Company, Astrazeneca, Abbvie; Travel expenses: Kite, a Gilead Company
